AstraZeneca: disappointing results for Farxiga in Covid
(CercleFinance.com) - AstraZeneca has reported disappointing results in the primary analysis of the phase III DARE-19 trial evaluating the potential of Farxiga (dapagliflozin) to treat patients hospitalised with Covid-19 who are at risk of developing serious complications.
The trial failed to reach statistical significance for prevention, measuring organ dysfunction and all-cause mortality, or for recovery, measuring a change in clinical status, at 30 days.
The 30-day safety and tolerability profile of the trial was consistent with the well-established safety profile of the drug. The full results of the trial will be presented at the American College of Cardiology Scientific Sessions in May.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The trial failed to reach statistical significance for prevention, measuring organ dysfunction and all-cause mortality, or for recovery, measuring a change in clinical status, at 30 days.
The 30-day safety and tolerability profile of the trial was consistent with the well-established safety profile of the drug. The full results of the trial will be presented at the American College of Cardiology Scientific Sessions in May.
Copyright (c) 2021 CercleFinance.com. All rights reserved.